Prestige Biopharma's pancreatic cancer drug candidate put on FDA fast track

Korea Biomedical Review

17 March 2023 - Prestige Biopharma said on Thursday that its new pancreatic cancer antibody drug candidate, PBP1510, (ulenistamab), was granted FDA fast track designation.

PBP1510 was also designated as an orphan drug by three regulators in 2020 including the FDA, the EMA and the MFDS in Korea.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track